How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/vonoprazan-amoxicillin-dual-therapy.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Vonoprazan-Amoxicillin Dual Therapy — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Vonoprazan-Amoxicillin Dual Therapy (Vonoprazan-Amoxicillin Dual Therapy) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Potassium-competitive acid blocker (PCAB) + beta-lactam antibiotic combination. Area: Gastroenterology / Infectious Disease.

marketed Potassium-competitive acid blocker (PCAB) + beta-lactam antibiotic combination H+/K+-ATPase (vonoprazan); bacterial cell wall peptidoglycan (amoxicillin) Gastroenterology / Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Vonoprazan-Amoxicillin Dual Therapy (Vonoprazan-Amoxicillin Dual Therapy) — Nanjing First Hospital, Nanjing Medical University. Vonoprazan inhibits gastric acid secretion while amoxicillin kills Helicobacter pylori bacteria, together eradicating H. pylori infection.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Vonoprazan-Amoxicillin Dual Therapy TARGET	Vonoprazan-Amoxicillin Dual Therapy	Nanjing First Hospital, Nanjing Medical University	marketed	Potassium-competitive acid blocker (PCAB) + beta-lactam antibiotic combination	H+/K+-ATPase (vonoprazan); bacterial cell wall peptidoglycan (amoxicillin)
Vonoprazan + amoxicillin	Vonoprazan + amoxicillin	The Third Xiangya Hospital of Central South University	marketed	Potassium-competitive acid blocker (PCAB) + beta-lactam antibiotic combination	H+/K+-ATPase (vonoprazan); bacterial cell wall peptidoglycan (amoxicillin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Potassium-competitive acid blocker (PCAB) + beta-lactam antibiotic combination class)

Nanjing First Hospital, Nanjing Medical University · 1 drug in this class
The Third Xiangya Hospital of Central South University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Vonoprazan-Amoxicillin Dual Therapy — Competitive Intelligence Brief. https://druglandscape.com/ci/vonoprazan-amoxicillin-dual-therapy. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab